Puma Bio (PBYI) - Cash per Share

Corporate emblem and logo of Puma Bio (PBYI)

Breast cancer therapy development is accelerating thanks to AI screening and plant automation at Puma Biotechnology (PBYI). Monitoring cash per share demonstrates a balance between financial discipline and capital efficiency, while the 2.08 metric reflects current dynamics. Demand for oncology drugs remains crisis-resistant, and the environmental footprint is minimized through laboratory outsourcing and digital documentation.

Puma Biotechnology (PBYI) - Cash per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Puma Biotechnology

- stock value and consensus price forecast:
- cash position and cash flow details:
General company analysis:Puma Biotechnology, Inc., PBYI
Manufactured product of Puma Biotechnology, Inc.

An investment audit of Puma Biotechnology (PBYI) requires an assessment of the liquid reserve via the equity value of free cash flow per share, which allows for the identification of hidden cash gaps. Amidst the stagnation of new NERLYNX appointments and dependence on a mature patent, an analysis of cash per share confirms the company's ability to maintain operational resilience despite limited capital inflows.